Investors

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten

Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lymphoma and CLL with CNS

Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement Data presented at the American Association for Cancer

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within the first year of the extension SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics,

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T.

Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up

Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.

Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibition Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) in a closed inactive state Phase 1 trial ongoing as

Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation